8 questions we still have about Trump’s case of Covid-19 – STAT
We sorted through some of our biggest remaining questions about Trump and his infection, some of which could be answered in the coming days.
Related Articles
Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics
In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build a genetic medicine.
STAT Madness Application
Enter to compete in this year’s STAT Madness! STAT Madness is a bracket-style tournament to find the best innovations in science and medicine from
STAT Madness Application
Enter to compete in this year’s STAT Madness! STAT Madness is a bracket-style tournament to find the best innovations in science and medicine from
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
South African regulator decides Vertex provides sufficient access to CF drugs, angering activists
South African regulators decided Vertex Pharmaceuticals has provided sufficient access to its cystic fibrosis medications, ending a high-profile episode that placed the company on the…
Pfizer’s blockbuster Ibrance slows tumor progression in another type of breast cancer
The efficacy data could help cushion Ibrance’s losses of market share to Kisqali, a similar drug from Novartis.
For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission
Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them “another can to kick.”
GLP-1 drugs spark disagreements in Trump’s circle
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey hey, this is…
HHMI’s move to diversify funding sparks debate about ‘biomedical elite’
HHMI will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for funds to be awarded in 2027.
Editas Medicine lays off 65% of staff and shelves lead gene-editing program
The CRISPR pioneer Editas Medicine announced layoffs and abandoned its lead sickle-cell program.